Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a) (NCT07327840)
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of Kylo-11 in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and elevated Lp(a).
Who can join: Review the eligibility criteria below.
Location: Alliance Clinical - Los Angeles — Los Angeles, California
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (59 Sites)
Showing the first 25 of 59 sites.
- Alliance Clinical - Los Angeles — Los Angeles, California
- Alliance Clinical - San Diego — San Diego, California
- FOMAT - Comprehensive Cardiovascular Care-Santa Maria California — Santa Maria, California
- Excel Medical Trials - Flourish Research — Boca Raton, Florida
- Clinical Research of West Florida (CRWF) - Clearwater — Clearwater, Florida
- Arrow Clinical Trials LLC — Daytona Beach, Florida
- Family Research and Healthcare Center Inc. — Doral, Florida
- Family Research Centers - Hialeah — Hialeah, Florida
- Jacksonville Center for Clinical Research — Jacksonville, Florida
- Universal Axon Clinical Research — Miami, Florida
- Clinical Research of West Florida (CRWF) - Tampa — Tampa, Florida
- Emory Healthcare-Emory Heart & Vascular Center - Executive Park — Atlanta, Georgia
- Centricity Research - Columbus — Columbus, Georgia
- Care Access-Lake Charles, LA — Lake Charles, Louisiana
- Alliance Clinical Las Vegas Excel Clinical Research — Las Vegas, Nevada
- Centricity Research d/b/a Lucas Research, Inc. — Morehead City, North Carolina
- Peking University First Hospital — Beijing, Beijing Municipality
- The First Affiliated Hospital of Baotou Medical College — Baotou,
- Beijing Anzhen Hospital — Beijing,
- Beijing Chao-Yang Hospital, Capital Medical University — Beijing,
- China-Japan Union Hospital of Jilin University — Changchun,
- The First People's Hospital of Changde — Changde,
- The Third Xiangya Hospital of Central South University — Changsha,
- Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital — Chengdu,
- Chongqing University Three Gorges Hospital — Chongqing,
📞 Contact the Study Coordinator
Phone: +86-18936916318
Email: zhangqsh@hygieiapharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lipoprotein Disorder
- A Study of DII235 in Adults With Elevated Lipoprotein(a) — Birmingham, Alabama
- Extreme Lipids Repository — Dallas, Texas
Explore by condition: All Lipoprotein Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.